Skip to main content
TipRanks
Go Ultimate75% OFF

Sensus Healthcare (SRTS) AI Stock Analysis

430 Followers
SRTS

Sensus Healthcare

(NASDAQ:SRTS)

Select Model
Rating:48Neutral
Price Target:$2.50▲(6.84% Upside)
Action:reiterated
Date:11/14/26

SRTS scores below average primarily due to deteriorating financial performance (shrinking revenue, sharply negative TTM margins, and heavy TTM cash burn). Technicals also weigh on the score as the stock trades below key moving averages with weak momentum. Offsetting these negatives, the company maintains very low leverage and the earnings call highlighted improving gross margin/adjusted EBITDA and potential reimbursement tailwinds, but execution and revenue conversion remain the key uncertainties.

Positive Factors
Very Low LeverageMinimal debt materially reduces solvency and refinancing pressure while preserving financial flexibility. This gives Sensus more room to fund operations, support commercialization, or absorb volatility without the added burden of substantial interest obligations.
Negative Factors
Shrinking Revenue BaseThe sustained decline in revenue shows that the company has not yet converted its commercial opportunities into durable top-line growth. A shrinking revenue base reduces operating leverage, limits the ability to absorb fixed costs, and makes a return to profitability more difficult.

Sensus Healthcare Key Performance Indicators (KPIs)

Revenue by GeographyBreaks down revenue across regions to show where Sensus earns its sales. For this small med‑tech firm, the split reveals dependence on key markets (and associated reimbursement or regulatory risk), highlights where expansion is succeeding, and signals how diversified the company’s growth prospects are.

$0.00$2.50M$5.00M$7.50M$10.00M$12.50MMar 21Jun 21Sep 21Dec 21Mar 22Jun 22Sep 22Dec 22Mar 23Jun 23Sep 23Dec 23Mar 24Jun 24Sep 24Dec 24Mar 25Jun 25Sep 25Dec 25Mar 26Jun 26
Chart Insights

Revenue is heavily China‑dependent, which creates the lumpy, high‑variance quarters and explains most of the recoveries after troughs; the occasional large “Other” spikes look like one‑off customer/timing events. The pronounced China drop in late‑2024 reads as a recognition/timing anomaly followed by a strong rebound through early 2026, supporting management’s view of sequential improvement, but international shipments and rental/Fair‑Deal mix have compressed ASPs and margins—geographic concentration keeps revenue volatile until recurring SensusLink/service revenue meaningfully ramps.

Data provided by:The Fly

Sensus Healthcare (SRTS) vs. SPDR S&P 500 ETF (SPY)

-60%-40%-20%0%20%40%SRTS-42.08%SPY+13.31%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
$38.27M
Dividend Yield
―
Average Volume (3M)
200.47K
Price to Earnings (P/E)
-2.4
Beta (1Y)
0.19
Revenue Growth
-53.33%
EPS Growth
-429.93%
Country
US
Employees
60
Sector
Healthcare
Sector Strength
51
Industry
Medical - Devices

Sensus Healthcare Business Overview & Revenue Model

Company Description

Sensus Healthcare, Inc. operates as a medical technology enterprise, manufacturing and distributing radiation therapy apparatuses to medical institutions across the globe. The company's portfolio leverages superficial radiation therapy (SRT), a cutti...

How the Company Makes Money

Sensus Healthcare generates revenue primarily by selling radiation therapy systems to medical practices, clinics, and hospitals. In addition to upfront system sales, the company earns revenue from recurring and ancillary sources tied to its installed...

Sensus Healthcare Earnings Call Summary

Earnings Call Date:Nov 12, 2026(Q3-2026)|% Change Since:-27.33%|Next Earnings Date:Feb 11, 2027
Earnings Call SentimentPositive

The call was broadly constructive and focused on commercial progress, including the placement of the 1,000th system, higher shipments, stronger gross margin, improved adjusted EBITDA, broader customer engagement, recurring revenue initiatives, and international opportunities. These positives were partially offset by a 13% revenue decline, a larger reported net loss, lower cash, delayed shipments from financing issues, and the need to convert the expanding pipeline into revenue.

Positive Updates

1,000th SRT System Placed
Sensus recently placed its 1,000th SRT system, marking a milestone in building its installed base and physician customer relationships.

Negative Updates

Revenue Declined 13%
Third-quarter revenue was $6.0 million compared with $6.9 million in the third quarter of 2025, a decline of 13%. The year-over-year difference was driven primarily by product mix, with more lower-priced SRT-100 systems relative to SRT-100 Vision systems, and no sales to the historically largest customer during the quarter.

Company Guidance

Management said its 5 priorities remain unchanged and that it expects to build on this momentum in the fourth quarter, while it “fully expect[s] that 26% to take effect on January 1 in the hospital environment” and confirmed this should occur on 1/1/'27; it also intends to be disciplined as it pursues international expansion, will attend conferences in Europe and Korea during the fourth quarter, aims to place SRT systems in every facility across groups with “about 450-or-more practices nationwide,” and said Sensus Link is seeing customers “all signing up for it.”

Sensus Healthcare Financial Statement Overview

Summary

Overall fundamentals are weak despite a low-debt balance sheet. The income statement has deteriorated materially (revenue down sharply from 2024 to 2025 and further in TTM; margins flipped from positive to deeply negative), and cash flow has turned to significant TTM cash burn. The balance sheet is a relative strength with minimal debt, but equity has declined and returns on equity are sharply negative, reflecting ongoing losses.

Income Statement

22Negative

Balance Sheet

72Positive

Cash Flow

28Negative
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue16.62M27.48M41.81M24.41M44.53M27.04M
Gross Profit6.95M11.87M24.43M14.06M29.63M16.99M
EBITDA-11.35M-9.00M9.45M1.11M28.50M4.73M
Net Income-16.04M-7.72M6.65M485.00K24.24M4.12M
Balance Sheet
Total Assets40.55M53.04M62.16M53.71M56.73M32.24M
Cash, Cash Equivalents and Short-Term Investments12.92M22.08M22.06M23.15M25.52M14.52M
Total Debt278.00K680.00K602.00K783.00K1.02M225.00K
Total Liabilities5.11M4.94M6.34M4.87M8.67M6.22M
Stockholders Equity35.44M48.10M55.83M48.84M48.07M26.02M
Cash Flow
Free Cash Flow-11.51M332.00K-1.11M-2.37M-1.57M-414.00K
Operating Cash Flow-11.35M528.00K-831.00K-2.15M-1.41M-286.00K
Investing Cash Flow-174.00K-196.00K-276.00K-187.00K14.84M129.00K
Financing Cash Flow-5,000-305.00K15.00K-40.00K-2.43M-231.00K

Sensus Healthcare Technical Analysis

Technical Analysis SentimentNegative
Last Price2.34

Price Trends

50DMA2.96Negative
100DMA3.03Negative
200DMA3.42Negative

Market Momentum

MACD-0.04Positive
RSI35.96Neutral
STOCH7.73Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SRTS, the sentiment is Negative. The current price of 2.34 is below the 20-day moving average (MA) of 2.91, below the 50-day MA of 2.96, and below the 200-day MA of 3.42, indicating a bearish trend. The MACD of -0.04 indicates Positive momentum. The RSI at 35.96 is Neutral, neither overbought nor oversold. The STOCH value of 7.73 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SRTS.

Sensus Healthcare Risk Analysis

Sensus Healthcare disclosed 24 risk factors in its most recent earnings report. Sensus Healthcare reported the most risks in the "Finance & Corporate" category.

Higher RiskSector Avg.Lower RiskFinance & CorporateTech & InnovationLegal & RegulatoryProductionAbility to SellMacro & Political
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy

Latest Risks Added

1 New Risk
1.Pandemics, natural disasters, global climate change, acts of terrorism and global conflicts may have a negative impact on our business and operations.Q4, 2023

Sensus Healthcare Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

SRTS against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
INMDINMD69Neutral$763.61M10.7911.36%―2.50%-43.86%
PENPEN67Neutral$12.65B80.4310.44%―16.98%-5.62%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
SRTSSRTS48Neutral$38.27M-2.40-38.65%―-53.33%-429.93%
ARAYARAY41Neutral$8.40M-0.48-36.60%―-12.50%5.33%
IRIXIRIX40Underperform$12.12M-3.39-78.94%―3.68%36.91%
NNOXNNOX40Underperform$25.36M-0.19-94.35%―31.52%-89.07%

* Healthcare Sector Average

Performance Comparison

-50%0%50%SRTSARAYIRIXPENINMDNNOXDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
SRTS and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
SRTSSensus Healthcare, Inc.2.34-1.70-42.08%
ARAYAccuray Incorporated2.55-36.32-93.44%
IRIXIridex0.69-0.24-26.13%
PENPenumbra Inc.320.6242.5215.29%
INMDInmode13.15-1.00-7.07%
NNOXNano-X Imaging Ltd.0.32-2.99-90.33%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 14, 2026